These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 2241097)

  • 1. A potential role for antisense oligonucleotide analogues in the development of oncogene targeted cancer chemotherapy.
    Tidd DM
    Anticancer Res; 1990; 10(5A):1169-82. PubMed ID: 2241097
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antisense oligonucleotides as therapeutics for malignant diseases.
    Ho PT; Parkinson DR
    Semin Oncol; 1997 Apr; 24(2):187-202. PubMed ID: 9129689
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The therapeutic potential of antisense oligonucleotides.
    Sharma HW; Narayanan R
    Bioessays; 1995 Dec; 17(12):1055-63. PubMed ID: 8634067
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of chronic myelogenous leukemia cells harboring a BCR-ABL B3A2 junction by antisense oligonucleotides targeted at the B2A2 junction.
    Mahon FX; Ripoche J; Pigeonnier V; Jazwiec B; Pigneux A; Moreau JF; Reiffers J
    Exp Hematol; 1995 Dec; 23(14):1606-11. PubMed ID: 8542954
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antisense oligonucleotides and prevention of tumor growth: a different approach and proposal for a new method.
    Yildiz D; Oztas H; Hilal Ates B
    Med Hypotheses; 2005; 64(2):328-32. PubMed ID: 15607566
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antisense attenuation of Wnt-1 and Wnt-3a expression in whole embryo culture reveals roles for these genes in craniofacial, spinal cord, and cardiac morphogenesis.
    Augustine K; Liu ET; Sadler TW
    Dev Genet; 1993; 14(6):500-20. PubMed ID: 8111977
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antisense inhibition of oncogene expression.
    Neckers L; Whitesell L; Rosolen A; Geselowitz DA
    Crit Rev Oncog; 1992; 3(1-2):175-231. PubMed ID: 1312868
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Suppression of gene expression by targeted disruption of messenger RNA: available options and current strategies.
    Jen KY; Gewirtz AM
    Stem Cells; 2000; 18(5):307-19. PubMed ID: 11007915
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Applications of antisense oligonucleotides in oncology.
    Pierga JY; Magdelenat H
    Cell Mol Biol (Noisy-le-grand); 1994 May; 40(3):237-61. PubMed ID: 7920172
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antisense approaches to cancer gene therapy.
    Mercola D; Cohen JS
    Cancer Gene Ther; 1995 Mar; 2(1):47-59. PubMed ID: 7621254
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Not nonsense but antisense--applications of antisense oligonucleotides in different fields of medicine.
    Oberbauer R
    Wien Klin Wochenschr; 1997 Jan; 109(2):40-6. PubMed ID: 9123943
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of human papillomavirus type 18-specific antisense oligonucleotides on the transformed phenotype of human carcinoma cell lines.
    Steele C; Cowsert LM; Shillitoe EJ
    Cancer Res; 1993 May; 53(10 Suppl):2330-7. PubMed ID: 7683572
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antisense molecules for targeted cancer therapy.
    Wacheck V; Zangemeister-Wittke U
    Crit Rev Oncol Hematol; 2006 Jul; 59(1):65-73. PubMed ID: 16750913
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antisense oligonucleotide technology in the development of cancer therapeutics.
    Tseng BY; Brown KD
    Cancer Gene Ther; 1994 Mar; 1(1):65-71. PubMed ID: 7621240
    [No Abstract]   [Full Text] [Related]  

  • 15. Evaluation of N-ras oncogene anti-sense, sense and nonsense sequence methylphosphonate oligonucleotide analogues.
    Tidd DM; Hawley P; Warenius HM; Gibson I
    Anticancer Drug Des; 1988 Aug; 3(2):117-27. PubMed ID: 2457379
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Kinetic selectivity of complementary nucleic acids: bcr-abl-directed antisense RNA and ribozymes.
    Kronenwett R; Haas R; Sczakiel G
    J Mol Biol; 1996 Jun; 259(4):632-44. PubMed ID: 8683570
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antisense oligonucleotide derivatives as gene-targeted drugs.
    Knorre DG; Vlassov VV
    Biomed Sci; 1990 Apr; 1(4):334-43. PubMed ID: 1723003
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The myc family of oncogenes and their presence and importance in small-cell lung carcinoma and other tumour types.
    Prins J; De Vries EG; Mulder NH
    Anticancer Res; 1993; 13(5A):1373-85. PubMed ID: 8239508
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of Down's syndrome critical locus gene SIM2-s as a drug therapy target for solid tumors.
    DeYoung MP; Tress M; Narayanan R
    Proc Natl Acad Sci U S A; 2003 Apr; 100(8):4760-5. PubMed ID: 12676991
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antisense therapy for cancer.
    Gleave ME; Monia BP
    Nat Rev Cancer; 2005 Jun; 5(6):468-79. PubMed ID: 15905854
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.